C. Schmeck

发表

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Stefan Willmann, Carsten Schmeck, F. Hafner, 2012, British journal of clinical pharmacology.

Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure

E. Pook, P. Kolkhof, T. Mondritzki, 2020, European journal of heart failure.

Dibenzodioxocinones--a new class of CETP inhibitors.

F. Hafner, V. Li, A. Vakalopoulos, 2005, Bioorganic & medicinal chemistry letters.

Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.

M. Pavkovic, E. Pook, P. Kolkhof, 2019, Journal of Cardiovascular Pharmacology.

Differentiation of Arginine Vasopressin Antagonistic Effects by Selective V2 versus Dual V2/V1a Receptor Blockade in a Preclinical Heart Failure Model

M. Gheorghiade, H. Sabbah, P. Kolkhof, 2011, American journal of therapeutics.

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.

C. Kohlsdorfer, G. Wensing, M. Boettcher, 2012, British journal of clinical pharmacology.

Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease.

A. Ehrmann, F. Eitner, K. Lustig, 2020, American journal of physiology. Renal physiology.

Novel heterocyclic thyromimetics.

J. Pernerstorfer, C. Schmeck, A. Kretschmer, 2005, Bioorganic & medicinal chemistry letters.

Novel heterocyclic thyromimetics. Part 2.

H. Bischoff, C. Schmeck, A. Kretschmer, 2007, Bioorganic & medicinal chemistry letters.

A useful application of benzyl trichloroacetimidate for the benzylation of alcohols

C. Schmeck, T. Huhn, U. Groth, 1993 .

Synthesis of Optically Active 4-Substituted 2-Aminobutyrolactones and Homoserines by Combined Aldol/Photocyclization Reactions of Chromium Aminocarbene Complexes

L. Hegedus, C. Schmeck, 1994 .

Asymmetric Synthesis via Heterocyclic Intermediates, LII. Synthesis of tert‐Leucine and Related Amino Acids

C. Schmeck, T. Huhn, U. Groth, 1993 .

Asymmetric Synthesis via Heterocyclic Intermediates. Part 52. Synthesis of tert-Leucine and Related Amino Acids.

C. Schmeck, T. Huhn, U. Groth, 1993 .

Small molecules and their impact in drug discovery: a perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory.

C. Schmeck, Michael W. Härter, H. Beck, 2022, Drug discovery today.

Cholesteryl ester transfer protein and its inhibition

Olaf Weber, H. Bischoff, C. Schmeck, 2010, Cellular and Molecular Life Sciences.

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.

Alexander Hillisch, Heinrich Meier, Mario Lobell, 2006, Drug discovery today.

Asymmetric Synthesis via Heterocyclic intermediates, L. – Trichloroacetimidates, II. Asymmetric Synthesis of α‐Amino Acid Benzyl Esters via the Bisbenzyl Bislactim Ether of cyclo(‐L‐Val‐Gly‐)

C. Schmeck, U. Groth, U. Schöllkopf, 1993 .

In Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits

Alexander Hillisch, Heinrich Meier, Mario Lobell, 2006, ChemMedChem.

Novel tetrahydrochinoline derived CETP inhibitors.

Heike Gielen-Haertwig, Olaf Weber, H. Bischoff, 2010, Bioorganic & medicinal chemistry letters.

Chromanol derivatives--a novel class of CETP inhibitors.

H. Paulsen, Olaf Weber, H. Bischoff, 2011, Bioorganic & medicinal chemistry letters.

Novel tetrahydrochinoline derived CETP inhibitors.

Heike Gielen-Haertwig, Olaf Weber, H. Bischoff, 2010, Bioorganic & medicinal chemistry letters.